AKT1 and prostate cancer: It has been reported that AZD5363, an AKT inhibitor potently inhibited proliferation and induced apoptosis in prostate cancer cell lines expressing the AR and had anticancer activity in vivo in androgen-sensitive and castration-resistant phases of a LNCaP xenograft model [20].